# EDGAR Filing Document

**Accession Number:** 0000890821
**File Stem:** 0001493152-25-019095
**Filing Date:** 2025-10
**Character Count:** 25829
**Document Hash:** 263f3edfe1cb4b093c7b1287aca6d8dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-019095.hdr.sgml**: 20251023

**ACCESSION NUMBER**: 0001493152-25-019095

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251022

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251023

**DATE AS OF CHANGE**: 20251023

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enveric Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0000890821
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954484725
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38286
- **FILM NUMBER:** 251413463

**BUSINESS ADDRESS:**
- **STREET 1:** 245 FIRST STREET RIVERVIEW II 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 239-302-1707

**MAIL ADDRESS:**
- **STREET 1:** 245 FIRST STREET RIVERVIEW II 18TH FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERI Holdings, Inc.
- **DATE OF NAME CHANGE:** 20150527

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPATIALIZER AUDIO LABORATORIES INC
- **DATE OF NAME CHANGE:** 19950323

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**October 22, 2025**

**Date of Report (Date of earliest event reported)**

**Enveric Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38286** | **95-4484725** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**Enveric Biosciences, Inc.**

**245 First Street, Riverview II, 18th Floor**

**Cambridge** **, MA 02142** 

**(Address of principal executive offices) (Zip code)**

**Registrant's telephone number, including area code: (239) 302-1707**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.01 per share | ENVB | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** 

*Stockholders' Equity* 

 

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 29, 2025 (the "Original 8-K"), Enveric Biosciences, Inc. (the "Company") received a notice from The Nasdaq Stock Market (the "Nasdaq") indicating that it no longer met the continued listing requirements. Specifically, the Company's stockholders' equity was below the minimum required stockholders' equity of $2.5 million as stipulated by Nasdaq Listing Rule 5550(b)(1) ("Rule 5550(b)(1)").

As noted in the Original 8-K, the Company had until October 10, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on October 10, 2025. The Company is filing this Current Report on Form 8-K (this "Current Report") to provide an update to its compliance with continued listing requirements as set forth in Rule 5550(b)(1).

On September 17, 2025, the Company entered into warrant exercise inducement offer letters (the "Inducement Letters") with certain institutional investors (the "Holders") that held certain outstanding (a) Series A Common Stock Purchase Warrants to purchase up to an aggregate of 1,224,999 shares of the Company's common stock, par value $0.01 per share (the "Common Stock"), and (b) Series B Common Stock Purchase Warrants to purchase up to an aggregate of 1,199,999 shares of Common Stock, both originally issued to the Holders on February 3, 2025, at an exercise price of $3.00 per share (collectively, the "Existing Warrants"). Pursuant to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $0.915 per share in consideration for the Company's agreement to issue in a private placement (x) the Series C Common Stock Warrants to purchase up to 2,449,998 shares of Common Stock and (y) the Series D Common Stock Warrants to purchase up to 2,399,998 shares of Common Stock (the "Warrant Inducement"). The Series C Common Stock Warrants and Series D Common Stock Warrants will only become exercisable if and when the Company obtains stockholder approval in accordance with Nasdaq Listing Rule 5635(d). The Series C Common Stock Warrants expire on the five (5)-year anniversary of receiving stockholder approval. The Series D Common Stock Warrants expire on the 18-month anniversary of receiving stockholder approval.

The closing of the transactions contemplated pursuant to the Inducement Letters occurred on September 18, 2025. The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducting placement agent fees and other offering expenses payable by the Company.

In that regard, as a result of the Warrant Inducement, as of the date of this Current Report, the Company believes its stockholders' equity exceeds $2.5 million as required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting.

*Minimum Bid Price and Excessive Reverse Stock Split*

On October 22, 2025, the Company received written notice (the "Notice") from the Listing Qualifications Department of Nasdaq notifying the Company that, because the closing price for the Company's Common Stock had fallen below $1.00 per share for 30 consecutive trading days, the Company was no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) ("Rule 5550(a)(2)"). Further, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period.

The Notice stated that unless the Company timely requests a hearing before a Hearings Panel (the "Panel"), the Company's securities would be subject to suspension/delisting. Accordingly, the Company intends to timely request a hearing with the Panel, and at which point, such timely request will automatically stay any further suspension or delisting action by Nasdaq at least pending the ultimate conclusion of the hearing process. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq.

**Item 3.03 Material Modification to Rights of Security Holders.**

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report is incorporated herein by reference.

**Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On October 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of Delaware to effect a 1-for-12 reverse stock split of the shares of the Company's Common Stock, either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on October 28, 2025 (the "Reverse Stock Split"). At the Company's annual meeting of stockholders on May 29, 2025, the Company's stockholders conditionally approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of the Company's Common Stock at a ratio in the range of 1-for-5 to 1-for-50, upon the Company receiving a delisting determination from the Nasdaq Capital Market ("Nasdaq") for failure to maintain the required minimum bid price under Rule 5550(a)(2), with such ratio to be determined by the Company's board of directors (the "Board") and included in a public announcement. As further described in Item 3.01 to this Current Report, on October 22, 2025, the Company received a delisting determination from Nasdaq. The Board determined to effect the Reverse Stock Split at a ratio of 1-for-12 and approved the corresponding final form of the Certificate of Amendment.

As a result of the Reverse Stock Split, every 12 shares of issued and outstanding Common Stock will be automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Any fractional shares that would otherwise have resulted from the Reverse Stock Split will be rounded up to the next whole number. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 6,219,568 shares to approximately 518,297 shares, subject to adjustment for the rounding up of fractional shares. The number of authorized shares of Common Stock under the Certificate of Incorporation will remain unchanged at 100,000,000 shares.

Proportionate adjustments will be made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of Common Stock reserved for future issuance under the Company's 2020 Long-Term Incentive Plan, as amended.

The Common Stock will begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on October 28, 2025. The trading symbol for the Common Stock will remain "ENVB." The new CUSIP number for the Common Stock following the Reverse Stock Split is 29405E505.

For more information about the Reverse Stock Split, see the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 15, 2025, the relevant portions of which are incorporated herein by reference. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated by reference herein.

**Item 8.01 Other Events.**

On October 23, 2025, the Company issued a press release with respect to the Reverse Stock Split. A copy of such press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

**Forward-Looking Statements**

This Current Report contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans,"" expects" "proposes," "budgets," "schedules," "estimates," "forecasts," "intends," "anticipates," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of various factors. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable based on information currently available, the Company cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. In any event, these statements speak only as of the date of this Current Report. The parties undertake no obligation to revise or update any of the forward-looking statements to reflect events or circumstances after the date of this Current Report or to reflect new information or the occurrence of unanticipated events.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 3.1 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc.](ex3-1.htm) |
| 99.1 | [Press Release dated October 23, 2025](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | October 23, 2025 | **ENVERIC BIOSCIENCES, INC.** | **ENVERIC BIOSCIENCES, INC.** |
|  |  | By: | */s/ Joseph Tucker* |
|  |  |  | Joseph Tucker |
|  |  |  | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT**

**TO**

**AMENDED AND RESTATED CERTIFICATE OF INCORPORATION**

**OF**

**ENVERIC BIOSCIENCES, INC.**

Enveric Biosciences, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that:

1. The name of the Corporation is Enveric Biosciences, Inc.

2. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation, as amended of the Corporation and declaring said amendment to be advisable.

3. Effective as of 8:00 am, New York time, on October 28, 2025 (the "Effective Time"), each twelve (12) issued and outstanding shares of the Corporation's Common Stock, par value $0.01 per share, shall be converted into one (1) share of the Corporation's Common Stock, par value $0.01 per share, as constituted following the Effective Time.

4. The Certificate of Incorporation is hereby amended by adding the following paragraph G to ARTICLE IV:

"G. Reverse Stock Split.

Upon the effectiveness of the filing of this Certificate of Amendment (the "Effective Time") each share of the Corporation's common stock, $0.01 par value per share (the "Old Common Stock"), either issued or outstanding or held by the Corporation as treasury stock, immediately prior to the Effective Time, will be automatically reclassified and combined (without any further act) into a smaller number of shares such that each twelve (12) shares of Old Common Stock issued and outstanding or held by the Company as treasury stock immediately prior to the Effective Time is reclassified into one share of Common Stock, $0.01 par value per share, of the Corporation (the "New Common Stock"), without increasing or decreasing the amount of stated capital or paid-in surplus of the Corporation (the "Reverse Stock Split"). The Board of Directors shall make provision for the issuance of that number of fractions of New Common Stock such that any fractional share of a holder otherwise resulting from the Reverse Stock Split shall be rounded up to the next whole number of shares of New Common Stock. Any stock certificate that, immediately prior to the Effective Time, represented shares of the Old Common Stock will, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent the number of shares of the New Common Stock into which such shares of Old Common Stock shall have been reclassified plus the fraction, if any, of a share of New Common Stock issued as aforesaid."

5. At an annual meeting of stockholders held on May 29, 2025, a majority of those stockholders who cast their votes duly approved, in accordance with Section 242 of the General Corporation Law of the State of Delaware, a reverse stock split of our common stock in a range between 1-for 5 and 1-for-50 and authorized the Board of Directors to approve the exact ratio of the reverse stock split.

IN WITNESS WHEREOF, Enveric Biosciences, Inc. has caused this Certificate to be duly executed by the undersigned duly authorized officer as of this 23rd day of October, 2025.

---

| | |
|:---|:---|
| ENVERIC BIOSCIENCES, INC. | ENVERIC BIOSCIENCES, INC. |
| By: | */s/ Joseph Tucker* |
| Name: | Joseph Tucker |
| Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Enveric Biosciences Announces Reverse Stock Split**

 

*Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025*

CAMBRIDGE, Mass., October 23, 2025 – Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. The reverse stock split will become effective at 8:00 a.m., New York time, on Tuesday, October 28, 2025. Enveric's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "ENVB" and will begin trading on a split-adjusted basis when the market opens on Tuesday, October 28, 2025.

At the Company's annual meeting of stockholders on May 29, 2025, the Company's stockholders conditionally approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of the Company's Common Stock at a ratio in the range of 1-for-5 to 1-for-50, upon the Company receiving a delisting determination from the Nasdaq Capital Market ("Nasdaq') for failure to maintain the required minimum bid price, with such ratio to be determined by the Company's board of directors (the "Board") and included in a public announcement. On October 22, 2025, the Company received a delisting determination from Nasdaq, and the Board determined to effect the reverse stock split at a ratio of 1-for-12 and approved the corresponding final form of the certificate of amendment.

At the effective time of the reverse stock split, every 12 shares of Enveric's issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-12 reverse stock split. It is not necessary for stockholders holding shares of the Company's common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will be rounded up to the nearest whole number of shares. The reverse stock split will reduce the number of shares of Enveric's common stock outstanding from 6,219,568 shares to approximately 518,297 shares. Proportional adjustments will be made to the number of shares of Enveric's common stock issuable upon exercise or conversion of Enveric's equity awards and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company's transfer agent, Equiniti Trust Company, LLC, at 800-468-9716.

**About Enveric Biosciences**

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂<sub>A</sub> and 5-HT₁<sub>B</sub> receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit <u>www.enveric.com</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: remain listed on Nasdaq, finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Contact**

**Investor Relations**

<u>Tiberend Strategic Advisors, Inc.</u><br> David Irish<br> (231) 632-0002<br> <u>dirish@tiberend.com</u>

**Media Relations**

<u>Tiberend Strategic Advisors, Inc.</u>

Casey McDonald

(646) 577-8520

<u>cmcdonald@tiberend.com</u>